Dermata Therapeutics Updates At-The-Market Offering Capacity to $705,000
DRMA sits 91% above its 52-week low of $1.58 on elevated volume (20× avg).
Summary
Dermata Therapeutics filed a prospectus supplement to update its At-The-Market (ATM) offering capacity, allowing it to sell up to an additional $705,000 in common stock.
Key Events · Financing and Capital Events · DRMA
-
Updates ATM Offering Capacity
The company can now sell up to an additional $705,000 of common stock through its At-The-Market (ATM) offering.
-
Ongoing Dilution
This update is part of an existing ATM program, which has already resulted in approximately $3.45 million in stock sales, indicating ongoing dilution for shareholders.
-
Capital for Operations
For a micro-cap company, securing this capital is vital for funding operations and extending its financial runway, despite the dilutive effect.
-
Regulatory Constraints
The offering is limited by SEC rules, specifically the one-third public float restriction for smaller reporting companies, indicating the company is near its maximum primary offering capacity.
Analysis · DRMA · Life Sciences
This filing updates Dermata Therapeutics' existing At-The-Market (ATM) offering, indicating the company can now sell up to an additional $705,000 worth of common stock. This capital raise, while dilutive, is crucial for a micro-cap company like Dermata Therapeutics to fund operations and extend its financial runway. The company has already sold approximately $3.45 million through this ATM program, and this update reflects the remaining capacity under SEC rules, specifically the one-third public float limitation for smaller reporting companies. This follows a recent S-3 registration for a separate resale offering by selling stockholders on January 22, 2026, and a significant personal investment by the CEO on January 8, 2026, which provided a positive signal amidst ongoing capital needs.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRMA was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.58 to $23.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.